JP2018526981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526981A5 JP2018526981A5 JP2018501159A JP2018501159A JP2018526981A5 JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5 JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cdr2
- cdr1
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021168124A JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
| EPPCT/EP2016/050296 | 2016-01-08 | ||
| PCT/EP2016/066845 WO2017009442A1 (en) | 2015-07-15 | 2016-07-14 | Humanized or chimeric cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Division JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526981A JP2018526981A (ja) | 2018-09-20 |
| JP2018526981A5 true JP2018526981A5 (enExample) | 2019-08-29 |
Family
ID=57757079
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501159A Pending JP2018526981A (ja) | 2015-07-15 | 2016-07-14 | ヒト化またはキメラｃｄ３抗体 |
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US11359015B2 (enExample) |
| EP (1) | EP3322727B1 (enExample) |
| JP (3) | JP2018526981A (enExample) |
| KR (2) | KR20250048113A (enExample) |
| CN (3) | CN108368172B (enExample) |
| AU (2) | AU2016293073B2 (enExample) |
| BR (1) | BR112018000696A2 (enExample) |
| CA (1) | CA2992380A1 (enExample) |
| DK (1) | DK3322727T3 (enExample) |
| EA (1) | EA201890305A1 (enExample) |
| ES (1) | ES3063317T3 (enExample) |
| FI (1) | FI3322727T3 (enExample) |
| IL (2) | IL256562B2 (enExample) |
| MX (2) | MX395317B (enExample) |
| NZ (1) | NZ739028A (enExample) |
| PL (1) | PL3322727T3 (enExample) |
| PT (1) | PT3322727T (enExample) |
| RS (1) | RS67909B1 (enExample) |
| SI (1) | SI3322727T1 (enExample) |
| UA (1) | UA128057C2 (enExample) |
| WO (1) | WO2017009442A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| KR102363220B1 (ko) | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| PL3322727T3 (pl) | 2015-07-15 | 2026-05-11 | Genmab A/S | Humanizowane lub chimeryczne przeciwciała cd3 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| PT3592769T (pt) | 2017-03-09 | 2024-07-31 | Genmab As | Anticorpos contra pd-l1 |
| WO2018208877A1 (en) * | 2017-05-09 | 2018-11-15 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| TWI728250B (zh) | 2017-06-21 | 2021-05-21 | 美商基利科學股份有限公司 | 靶向hiv gp120及cd3之多特異性抗體 |
| IL272159B2 (en) | 2017-08-04 | 2026-03-01 | Genmab As | PD-L1 and CD137 binding agents and their use |
| CR20250347A (es) | 2018-03-12 | 2025-09-23 | Genmab As | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463) |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| KR20210063351A (ko) * | 2018-08-28 | 2021-06-01 | 암브룩스, 인코포레이티드 | 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도 |
| WO2020247929A1 (en) | 2019-06-07 | 2020-12-10 | Adimab, Llc | High affinity anti-cd3 antibodies, and methods for their generation and use |
| CA3146123A1 (en) * | 2019-07-29 | 2021-02-04 | Russell B. Wilson | Antibodies to candida and uses thereof |
| WO2021048423A1 (en) | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| EP4121456A1 (en) | 2020-03-18 | 2023-01-25 | Genmab A/S | Antibodies binding to b7h4 |
| BR112022022730A2 (pt) | 2020-05-08 | 2023-02-14 | Genmab As | Método para tratar um linfoma não hodgkin de células b em um indivíduo humano |
| EP4210746A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| KR20230080437A (ko) | 2020-10-02 | 2023-06-07 | 젠맵 에이/에스 | Ror2에 결합할 수 있는 항체 및 ror2 및 cd3에 결합하는 이중특이적 항체 |
| AR125815A1 (es) | 2021-05-07 | 2023-08-16 | Genmab As | Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3 |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| JP2024530166A (ja) * | 2021-08-04 | 2024-08-16 | アブプロ コーポレーション | Ｃｄ３標的化抗体及びそれらの使用 |
| AR127298A1 (es) * | 2021-10-08 | 2024-01-10 | Genmab As | Anticuerpos que se unen a cd30 y cd3 |
| CN115368446B (zh) * | 2022-07-19 | 2025-08-08 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN121240884A (zh) | 2023-04-05 | 2025-12-30 | 根马布股份公司 | 包含与cd30和cd3结合的抗体的药用组合物 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| EP2314629B2 (en) | 2002-07-18 | 2022-11-16 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP5686953B2 (ja) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用 |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| SG10201808730VA (en) | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| ES2733067T3 (es) | 2008-12-19 | 2019-11-27 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| US9587021B2 (en) | 2011-05-21 | 2017-03-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| DK2838918T3 (da) | 2012-04-20 | 2019-08-12 | Merus Nv | Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler |
| CA2915412A1 (en) * | 2012-06-14 | 2013-12-19 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| EP2895203A4 (en) | 2012-06-15 | 2016-09-28 | Imaginab Inc | ANTIGENBINDING CONSTRUCTS FOR CD3 |
| US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
| US9963512B2 (en) | 2012-11-21 | 2018-05-08 | Pharmabcine Inc. | Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same |
| KR102363220B1 (ko) | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| WO2016110576A1 (en) | 2015-01-08 | 2016-07-14 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| PL3322727T3 (pl) | 2015-07-15 | 2026-05-11 | Genmab A/S | Humanizowane lub chimeryczne przeciwciała cd3 |
| CR20250347A (es) | 2018-03-12 | 2025-09-23 | Genmab As | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463) |
| EP4121456A1 (en) | 2020-03-18 | 2023-01-25 | Genmab A/S | Antibodies binding to b7h4 |
| KR20230080437A (ko) | 2020-10-02 | 2023-06-07 | 젠맵 에이/에스 | Ror2에 결합할 수 있는 항체 및 ror2 및 cd3에 결합하는 이중특이적 항체 |
-
2016
- 2016-07-14 PL PL16739459.2T patent/PL3322727T3/pl unknown
- 2016-07-14 CN CN201680054638.0A patent/CN108368172B/zh active Active
- 2016-07-14 WO PCT/EP2016/066845 patent/WO2017009442A1/en not_active Ceased
- 2016-07-14 SI SI201631947T patent/SI3322727T1/sl unknown
- 2016-07-14 CA CA2992380A patent/CA2992380A1/en active Pending
- 2016-07-14 CN CN202210585379.1A patent/CN114989302B/zh active Active
- 2016-07-14 KR KR1020257009196A patent/KR20250048113A/ko active Pending
- 2016-07-14 BR BR112018000696-3A patent/BR112018000696A2/en active IP Right Grant
- 2016-07-14 IL IL256562A patent/IL256562B2/en unknown
- 2016-07-14 EP EP16739459.2A patent/EP3322727B1/en active Active
- 2016-07-14 AU AU2016293073A patent/AU2016293073B2/en active Active
- 2016-07-14 US US15/744,317 patent/US11359015B2/en active Active
- 2016-07-14 FI FIEP16739459.2T patent/FI3322727T3/fi active
- 2016-07-14 EA EA201890305A patent/EA201890305A1/ru unknown
- 2016-07-14 MX MX2018000347A patent/MX395317B/es unknown
- 2016-07-14 UA UAA201801453A patent/UA128057C2/uk unknown
- 2016-07-14 NZ NZ739028A patent/NZ739028A/en unknown
- 2016-07-14 PT PT167394592T patent/PT3322727T/pt unknown
- 2016-07-14 CN CN202511003204.5A patent/CN120842408A/zh active Pending
- 2016-07-14 KR KR1020187004157A patent/KR102786353B1/ko active Active
- 2016-07-14 RS RS20260358A patent/RS67909B1/sr unknown
- 2016-07-14 JP JP2018501159A patent/JP2018526981A/ja active Pending
- 2016-07-14 ES ES16739459T patent/ES3063317T3/es active Active
- 2016-07-14 DK DK16739459.2T patent/DK3322727T3/da active
- 2016-07-14 IL IL310467A patent/IL310467A/en unknown
-
2018
- 2018-01-09 MX MX2022011002A patent/MX2022011002A/es unknown
-
2021
- 2021-10-13 JP JP2021168124A patent/JP7604351B2/ja active Active
-
2022
- 2022-05-09 US US17/739,934 patent/US12617854B2/en active Active
- 2022-05-09 US US17/739,940 patent/US20220389101A1/en active Pending
- 2022-05-09 US US17/739,923 patent/US20220380464A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201733A patent/AU2023201733A1/en not_active Abandoned
-
2024
- 2024-12-11 JP JP2024216521A patent/JP2025038049A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020048564A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| US8399624B1 (en) | Acceptor framework for CDR grafting | |
| JP2017505121A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2019501883A5 (enExample) | ||
| EP2050764A1 (en) | Novel polyvalent bispecific antibody format and uses thereof | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| JP2022504802A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2018522888A5 (enExample) | ||
| US20200148778A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
| JP2020502233A5 (enExample) | ||
| WO2021013142A1 (zh) | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 | |
| TW202200620A (zh) | 抗flt3抗體及組合物 | |
| JP2024516098A5 (enExample) | ||
| JP2023516941A5 (enExample) | ||
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JP2024533234A5 (enExample) | ||
| US20240034815A1 (en) | Heterodimeric antibodies that bind cd3 and gpc3 | |
| JP2022531552A5 (enExample) | ||
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies |